PERTH, AUSTRALIA: February 23, 2012 – Phylogica Ltd (ASX:PYC, XETRA:PH7), a leading Australian peptide drug discovery company, announced today that it has been granted a new US Patent (Patent no. 8063012) entitled: 'Neuroprotective peptide inhibitors of AP-1 signalling and uses thereof' (derived from international patent application PCT/AU2007/000092). This patent covers a new Phylomer peptide, PYC38, and its derivatives, which show potent rescue from death of brain cells in models of neuronal death associated with conditions such as stroke and traumatic brain injury.
Phylogica's CEO Dr Paul Watt said: “We are very pleased to have been granted this patent as it provides further validation of the biological activity of Phylomers against intracellular targets. This is important because Phylogica is rapidly establishing itself as a leader in the new frontier of identifying peptides, which not only get into cells, but also exert therapeutically relevant effects against targets within cells. About half of the discovery alliances that we are currently negotiating with the pharmaceutical and biotechnology industry are around the intracellular space.”
For further information please download PDF below:
